Innovative Diagnostic Portfolio AESKU.GROUP specializes in developing innovative in-vitro diagnostic products for autoimmune, infectious diseases, allergies, and food intolerances, offering opportunities to cross-sell their advanced test systems to healthcare providers seeking reliable and efficient diagnostic solutions.

Rapid Test Expansion The recent launch of quantitative SARS-CoV-2 antibody tests demonstrates AESKU's ability to adapt quickly to market needs, positioning the company as a biotech partner capable of providing timely, high-quality testing solutions during global health crises.

Web and Quality Tools The launch of the AESQC web portal and IFA QC product line indicates an emphasis on digital integration and quality assurance, opening sales channels for laboratory software and quality control products within diagnostic laboratories.

Growth Potential With revenues between 10 and 25 million dollars and a dedicated team of up to 200 employees, AESKU.GROUP is positioned to expand its market share, especially by leveraging its innovative diagnostic offerings and strategic product launches.

Market Opportunities Targeting healthcare providers and laboratories focused on autoimmune and infectious disease diagnostics offers significant potential for upselling and expanding AESKU's presence within the autoimmune testing sector, particularly as demand for early detection and reliable diagnostics increases.